Navigation Links
Orchid Cellmark Reports Third Quarter 2008 Financial Results

PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, today reported its financial results for the third quarter of 2008.

Total revenues were $14.9 million for the third quarter of 2008 compared to $15.6 million for the third quarter of 2007. The decrease in total revenues for the third quarter of 2008 compared to a year ago was largely due to lower revenues in the U.K.

Total U.S.-based revenues rose by 4% over the comparable quarter in 2007, principally due to increases in the U.S. paternity testing business. This was partially offset by lower revenues from forensic casework business as well as a decline in the company's business that generates DNA profiles for the federal CODIS (Combined DNA Index System) and state DNA databases. The decrease in U.K.-based revenues in the quarter compared to a year ago was due to lower volumes of animal DNA testing for scrapie susceptibility and slightly reduced forensics revenues due to adverse exchange rates.

Excluding cost of service revenue, operating expenses for the quarter declined to $5.8 million compared to $6.0 million for the third quarter of 2007 as a result of reduced general and administrative expenses.

Operating loss for the third quarter of 2008 was $1.4 million compared to a $466 thousand loss for the third quarter of 2007. The operating loss increase was principally due to decreases in gross margins in both the U.S. and the U.K. Gross margin for the U.S. business decreased for the third quarter of 2008 compared to the third quarter of 2007 largely as a result of a decline in the average selling prices in the CODIS and forensic casework businesses. Gross margin for the U.K. business in the quarter was adversely impacted by lower margin forensics revenues replacing the DNA testing volumes related to the loss of former LGC business and the buildup of casework management capabilities in the U.K. to service the business the company won under the North West/South West and Wales regional forensics services tender.

Orchid Cellmark reported a net loss of $1.5 million, or $(0.05) per share, for the third quarter of 2008 compared to a net loss of $707 thousand, or $(0.02) per share, for the third quarter of 2007. Net loss for the third quarter of 2008 and 2007 includes charges of $1.1 million and $1.2 million, respectively, for depreciation and amortization.

At September 30, 2008, cash and cash equivalents were $15.9 million.

Thomas Bologna, president and chief executive officer of Orchid Cellmark commented, "Our results for the third quarter reflect a challenging industry environment where pricing pressures, declining U.K. scrapie orders and adverse foreign exchange rates all contributed to the revenue decline, despite increases in forensics casework volume."

Mr. Bologna added, "We did achieve important gains in core business segments, including U.S. paternity, U.S. forensic casework in the Dallas facility and U.K. police force tender revenues. U.K. forensics crime revenue grew by 6% in the third quarter over the second quarter of this year, and would have made up completely for the loss of the LGC-related business had it not been for adverse foreign exchange rates. This is a considerable achievement given that the LGC business represented approximately 40% of U.K. revenues just a year ago."

Mr. Bologna concluded: "The challenges encountered in the third quarter will continue in the fourth quarter of 2008 and put downward pressure on our previously discussed operating targets. Specifically, the impact of the adverse foreign exchange rate, the timing of sample receipts in the U.S., and the continuing buildup of casework management capabilities in the U.K. will influence revenue and gross margin in the fourth quarter. However, we believe the fundamentals of our core business are sound; we have achieved efficiencies in our operations; and we have a strong balance sheet with $15.9 million in cash at the end of the quarter. The DNA identity testing market offers growth opportunities with market dynamics favorable in the U.S. and a changing market in the U.K. that affords us good prospects for gaining market share."

Conference Call Information

A conference call with Orchid Cellmark management will be held on Thursday, October 30, 2008 at 10:00 a.m. EDT. To listen to the conference call, please dial (877) 266-0703 or (706) 643-7682 and ask for the Orchid Cellmark conference call, conference number 70588526. To listen to the live or archived webcast via the Internet, please visit the Investors section of the company's web site at The webcast will be available for replay for 90 days after the conference call.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at

All statements in this press release that are not historical are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: expectations regarding Orchid Cellmark's business operations and outlook; the belief that the fundamentals of our core business are sound; and the belief that the DNA testing market offers growth opportunities with market dynamics favorable in the U.S. and a changing market in the UK that affords us good prospects for gaining market share. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, the risk that we are not able to replace the work that we previously provided to several police forces in the U.K. under an arrangement with LGC, the risk that the amount of revenue resulting from the North West/South West and Wales regional tender in the U.K. is not significant, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, and Orchid Cellmark's ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press release.


Investors: Media:

Mary Bashore Rick Anderson

Orchid Cellmark Inc. The Torrenzano Group

(609) 750-2324 (212) 681-1700

Orchid Cellmark Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

Three months and nine months ended September 30, 2008 and 2007

(In thousands, except per share data)


Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007


Service revenues $14,845 $15,511 $44,404 $45,100

Other revenues 27 47 219 222

Total revenues 14,872 15,558 44,623 45,322

Operating expenses:

Cost of service revenues 10,500 10,054 31,159 29,779

Research and development 228 264 654 832

Marketing and sales 1,536 1,503 4,659 4,500

General and administrative 3,588 3,831 12,639 11,747

Restructuring - (75) - (75)

Amortization of intangible assets 475 447 1,429 1,337

Total operating expenses 16,327 16,024 50,540 48,120

Operating loss (1,455) (466) (5,917) (2,798)

Other income, net 128 301 846 817

Loss before income tax expense (1,327) (165) (5,071) (1,981)

Income tax expense (benefit) 132 542 (117) 1,154

Net loss $(1,459) $(707) $(4,954) $(3,135)

Basic and diluted net loss per share $(0.05) $(0.02) $(0.17) $(0.11)

Shares used in computing basic and

diluted net loss per share: 29,935 29,327 29,935 29,323

Orchid Cellmark Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

September 30, 2008 and December 31, 2007

(In thousands)


September 30, December 31,

2008 2007


Current assets

Cash and cash equivalents $15,857 $20,918

Accounts receivable, net 11,319 9,516

Inventory 1,497 1,443

Prepaids and other current assets 2,041 2,151

Total current assets 30,714 34,028

Fixed assets, net 6,399 7,440

Goodwill 9,558 9,519

Other intangibles, net 8,185 9,694

Restricted cash - 958

Other assets 487 490

Total assets $55,343 $62,129

Liabilities and Stockholders' Equity:

Current liabilities

Accounts payable $2,668 $2,027

Accrued expenses and other current

liabilities 4,297 4,611

Income taxes payable - 543

Short-term debt and current portion of

long-term debt 385 428

Deferred revenue 852 964

Total current liabilities 8,202 8,573

Other liabilities 284 1,123

Total liabilities 8,486 9,696

Total stockholders' equity 46,857 52,433

Total liabilities and stockholders' equity $55,343 $62,129

SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Orchid Cellmark Reports Second Quarter 2008 Financial Results
2. Orchid Cellmark To Announce Second Quarter 2008 Financial Results on July 31, 2008
3. Orchid Cellmark Reports First Quarter 2008 Financial Results
4. Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services
5. Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
6. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
8. Orchid Cellmark Reports Third Quarter 2007 Financial Results
9. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
10. Gentiva Reports Third Quarter Revenue and Profit Growth
11. LegalView Reports on Rare Traumatic Brain Injury Condition That Could Cause Complete Paralysis of A Victim
Post Your Comments:
(Date:12/1/2015)... Los Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... the United States, today announced that its iconic bottle has won top honors in ... drinks category. The Company also announced that it has been selected as a ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since the start ... scientific research and discoveries, leading us to better understand the disease’s behavior. Globally, ... affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides insight on ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015  Today, AmerisourceBergen, a ... CareFront, a first-of-its-kind population health management program focused ... Designed to be built into existing employer benefit ... resources for their care and explains how to ... tools to help patients understand their treatment options ...
(Date:12/1/2015)... Dec. 1, 2015  Booth #3506 – Claymount is featuring ... annual meeting of the Radiological Society of North ... this year. Based in the Netherlands , ... Medical Systems (NYSE: VAR ) and is one of ... and solid state automatic exposure control systems for controlling dose ...
(Date:12/1/2015)... 1, 2015 --> ... van Leeuwenhoek Hospital (NKI-AVL), among the world,s largest ... Leksell Gamma Knife® Icon™, the company,s latest generation ... --> --> With the ... treatments, Leksell Gamma Knife Icon offers greatly enhanced ...
Breaking Medicine Technology: